An integrated analysis of three medulloblastoma clinical trials refines risk-stratification approaches for reducing toxicity and improving survival
Neuro-Oncology · 01.01.2026 · 28 (1) · 268-281
DOI: 10.1093/neuonc/noaf250 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology, online erschienen am 24.10.2025. Verfasst von Kyle S Smith und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Developmental Neurobiology, St. Jude Children's Research Hospital, Memphis (K.S.S., P.A.N.). Hauptthemen laut MEDLINE: Medulloblastoma, Cerebellar Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Chemoradiotherapy. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: St. Baldrick's Foundation, CCSG 5P30CA021765-43 Developmental Funds, American Lebanese Syrian Associated Charities.
Abstract (Originalsprache)
Background
The identification of clinical and molecular heterogeneity in medulloblastoma has produced risk-stratified therapy, but establishing the most effective yet least toxic regimens has remained elusive owing to numerous treatment options. To improve risk-stratification, we performed an integrated analysis from three clinical trials.
Methods
Medulloblastoma patients from ACNS0331/NCT00085735, ACNS0332/NCT00392327, and SJMB03/NCT00085202 were included if they had methylation profiling. Molecular groups [WNT, SHH, Group 3 (G3), and Group 4 (G4)], subgroups, and copy number variations were procured from methylation profiles and mutations from next-generation sequencing. Data was assembled into an interactive portal to capture patient characteristics. Cross-trial comparisons, univariable, and multivariable analyses were conducted and used to derive a risk-stratification schema.
Results
Eight hundred ninety-eight patients (WNT = 131, SHH = 151, G3 = 220, G4 = 396) were included. Progression-free-survival (PFS) distributions among analogous cross-trial cohorts were not different, demonstrating no survival advantage of any one therapy over another. The addition of carboplatin to high-dose craniospinal irradiation (HDCSI) containing regimen was selectively superior in PFS in G3/G4 subgroup 3 (P = 0.048) and G3/G4 subgroup 2 (P = 0.035) to HDCSI regimens without carboplatin. Nine actionable risk-stratified groups were identified consisting of 2 WNT groups (low, high-risk), 3 SHH groups (low-, average-, very-high-risk), and 4 G3/G4 groups (low-, average-, high-, and very-high-risk).
Conclusions
Our integrated cross-trial analysis suggests toxicity can be reduced by eliminating disproportionate differences in therapy in favor of a more uniform treatment backbone. Moreover, we propose and model a risk-classification system that identifies the most appropriate cohorts on which to trial significant dose reductions in craniospinal irradiation or select treatment intensifications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Developmental Neurobiology, St. Jude Children's Research Hospital, Memphis (K.S.S., P.A.N.).
- Center of Excellence for Neuro-Oncology Sciences (CENOS), St. Jude Children's Research Hospital, Memphis (K.S.S., P.A.N.).
- Division of Neuro-Oncology, Department of Oncology, St. Jude Children's Research Hospital, Memphis (S.K.D., A.G., G.W.R.).
- Department of Biostatistics, St. Jude Children's Research Hospital, Memphis (C.A.B., Y.L., Q.L., T.L., A.O.-T.).
- Department of Computational Biology, St. Jude Children's Research Hospital, Memphis (E.S., C.L., A.Z.P., K.G., X.Z.).
- Department of Radiation Oncology, Washington University School of Medicine, St Louis (J.M.M.).
ORCID-Profile: Maryam Fouladi, Amar Gajjar, Xin Zhou, Arzu Onar-Thomas, Giles W Robinson
Förderung
- St. Baldrick's Foundation
- CCSG 5P30CA021765-43 Developmental Funds
- American Lebanese Syrian Associated Charities
- NCI NIH HHS
- the National Cancer Institute
Zitieren
APA
Smith, K. S., Dhanda, S. K., Billups, C. A., Sioson, E., Lu, C., Peraza, A. Z., Gangwani, K., Li, Y., Li, Q., Lin, T., Michalski, J. M., Packer, R. J., Olson, J. M., Leary, S. E. S., Fouladi, M., Gajjar, A., Zhou, X., Onar-Thomas, A., Northcott, P. A., & Robinson, G. W. (2026). An integrated analysis of three medulloblastoma clinical trials refines risk-stratification approaches for reducing toxicity and improving survival. Neuro-Oncology, 28(1), 268-281. https://doi.org/10.1093/neuonc/noaf250
Vancouver
Smith KS, Dhanda SK, Billups CA, Sioson E, Lu C, Peraza AZ, et al. An integrated analysis of three medulloblastoma clinical trials refines risk-stratification approaches for reducing toxicity and improving survival. Neuro-Oncology. 2026;28(1):268-281. doi:10.1093/neuonc/noaf250
BibTeX
@article{Smith2026,
author = {Smith, Kyle S and Dhanda, Sandeep K and Billups, Catherine A and Sioson, Edgar and Lu, Congyu and Peraza, Airen Zaldivar and Gangwani, Karishma and Li, Yimei and Li, Qian and Lin, Tong and Michalski, Jeff M and Packer, Roger J and Olson, James M and Leary, Sarah E S and Fouladi, Maryam and Gajjar, Amar and Zhou, Xin and Onar-Thomas, Arzu and Northcott, Paul A and Robinson, Giles W},
title = {An integrated analysis of three medulloblastoma clinical trials refines risk-stratification approaches for reducing toxicity and improving survival},
journal = {Neuro-Oncology},
year = {2026},
volume = {28},
number = {1},
pages = {268--281},
doi = {10.1093/neuonc/noaf250}
}
EUVIMED